Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neurofibromatosis 1 2

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Polidocanol × Clear all
NCT06132165 2025-11-21

Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas

Massachusetts General Hospital

Phase 1 Completed
13 enrolled
CNS

Neurofibromatosis 1

NCT06120036 2025-02-21

Dosing and Tolerability of Deoxycholic Acid vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas

Massachusetts General Hospital

Phase 1 Completed
20 enrolled
CNS

Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡